Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation

BACKGROUND: Trimethoprim-sulfamethoxazole (TMP-SMX) is the drug of choice for anti-Pneumocystis jirovecii pneumonia (PcP) prophylaxis in kidney transplant recipients (KTR). Post-transplant management balances preventing PcP with managing TMP-SMX-related adverse effects. TMP-SMX dose reduction addres...

Descripción completa

Detalles Bibliográficos
Autores principales: Prasad, G. V. Ramesh, Beckley, Jill, Mathur, Mohit, Gunasekaran, Madhushankar, Nash, Michelle M., Rapi, Lindita, Huang, Michael, Zaltzman, Jeffrey S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451305/
https://www.ncbi.nlm.nih.gov/pubmed/30953458
http://dx.doi.org/10.1186/s12879-019-3944-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451305/
https://www.ncbi.nlm.nih.gov/pubmed/30953458
http://dx.doi.org/10.1186/s12879-019-3944-0

Ejemplares similares